High Sensitivity Chimerism Testing in Less Than 24 Hours
Already using AlloSeq HCT and need to access technical documents? Login here.
Every minute of laboratory time is valuable. AlloSeq HCT can help you save time with a simple workflow and powerful analysis software, all while achieving high sensitivity chimerism monitoring.
Engraftment monitoring (chimerism) testing evaluates the success of a hematopoietic stem cell transplant by measuring the relative percentage of the recipient and the donor DNA in the recipient’s post-transplant specimen. Engraftment monitoring may assist in detecting disease relapse or graft failure.
What is AlloSeq HCT?
AlloSeq HCT is a targeted NGS-based solution enabling precise measurement of engraftment following hematopoietic stem cell transplant for research applications.
- Sample to result in less than 24 hours
- Test up to 48 samples/run
- Targets 202 bi-allelic SNPs across 22 autosomes
- Validated for use on Illumina MiSeq
What are the benefits of AlloSeq HCT?
Assay
- 1 assay for genotyping and monitoring
- 1-step single reaction multiplexed PCR
- Highly sensitive – 0.22% limit of detection
- Accurate, precise, and reproducible results
- Streamlined workflow with minimal hands-on time within 3 hours
HCT Software
- Able to determine and automatically compare up to 3 genotypes in a single sample – donor(s) and recipient: useful for cord blood transplants
- User-friendly AlloSeq HCT software features automatic determination of informative loci, chimerism calculation, and result tracking
Simple AlloSeq HCT Workflow with Minimal Hands-On Time
How Does AlloSeq HCT Work?
The AlloSeq HCT assay enables the amplification and sequencing of 202 single nucleotide polymorphisms (SNPs) across all autosomal chromosomes. The AlloSeq HCT software automatically calculates % recipient and donor DNA in post-transplant samples.
Rapid Workflow with Automated Analysis
HOT: Hands-on time (based on 48 samples). TAT: Turn around time.
Perform Detailed Analysis with Just a Few Clicks
AlloSeq HCT Publications*
| Publication | First Author | Journal | Year |
|---|---|---|---|
| Utility of next-generation sequencing-based chimerism analysis for early relapse prediction following allogenic hematopoietic cell transplantation Read more | Lee H | International Journal of Molecular Sciences | 2024 |
| Comparison of two chimerism test strategies, next-generation sequencing versus a combination of short-tandem repeats and quantitative PCR Read more | Zhang A | Journal of Molecular Diagnostics | 2024 |
| New methods for the quantification of mixed chimerism in transplantation Read more | Picard C | Frontiers in Immunology | 2023 |
| Validation of next generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation Read more | Kakodkar P | Frontiers in Genetics | 2023 |
| Chimerism testing by next generation sequencing for detection of engraftment and early disease relapse in allogeneic hematopoietic cell transplantation and an overview of NGS Read more | Liacini A | International Journal of Molecular Sciences | 2023 |
| Immune cell lineage-specific chimerism testing by next generation sequencing for engraftment monitoring after allogeneic hematopoietic stem cell transplantation Read more | Wu C | Methods in Molecular Biology | 2023 |
| Quantification of chimerism and graft immune cell composition with AlloSeq HCT, a highly sensitive and precise next-generation sequencing assay, in patients post-hematopoietic stem cell transplantation Read more | Calderin-Sollet Z | Blood | 2020 |
| Publication | First Author | Journal | Year |
|---|---|---|---|
| Utility of next-generation sequencing-based chimerism analysis for early relapse prediction following allogenic hematopoietic cell transplantation Read more | Lee H | International Journal of Molecular Sciences | 2024 |
| Comparison of two chimerism test strategies, next-generation sequencing versus a combination of short-tandem repeats and quantitative PCR Read more | Zhang A | Journal of Molecular Diagnostics | 2024 |
| New methods for the quantification of mixed chimerism in transplantation Read more | Picard C | Frontiers in Immunology | 2023 |
| Validation of next generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation Read more | Kakodkar P | Frontiers in Genetics | 2023 |
| Chimerism testing by next generation sequencing for detection of engraftment and early disease relapse in allogeneic hematopoietic cell transplantation and an overview of NGS Read more | Liacini A | International Journal of Molecular Sciences | 2023 |
| Immune cell lineage-specific chimerism testing by next generation sequencing for engraftment monitoring after allogeneic hematopoietic stem cell transplantation Read more | Wu C | Methods in Molecular Biology | 2023 |
| Quantification of chimerism and graft immune cell composition with AlloSeq HCT, a highly sensitive and precise next-generation sequencing assay, in patients post-hematopoietic stem cell transplantation Read more | Calderin-Sollet Z | Blood | 2020 |
AlloSeq HCT and AlloSeq HCT Software is available as CE/IVD and Research Use Only (RUO). For local regulatory status, please contact CareDx. AlloSeq is a trademark or registered trademark of CareDx, Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. Research Use Only products are not to be used for diagnostic procedures. © 2025 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.
